Medical News / Role of Intravenous Iron in Spotlight At ESC Congress 2023

A pair of studies and focused guideline update from the European Society of Cardiology (ESC) Congress 2023 are highlighting the role of intravenous iron in patients with iron deficiency and heart failure with reduced ejection fraction (HFrEF). Results of the HEART-FID trial and a meta-analysis, which were presented the day after new guidance included a recommendation for intravenous iron supplementation, offered new insight into the optimal role of intravenous iron, with the HEART-FID detailing the safety and tolerability while the meta-analysis concluded use of intravenous iron could help reduce hospitalizations and cardiovascular death. Source: MDMag. To view the third party content, kindly click on the link below or read more. You will then leave this site and enter a third party site.

read more

Data from an analysis of the landmark CLEAR Outcomes trial suggests bempedoic acid could prove useful ... read more
At the European Society of Cardiology (ESC) Congress 2023, the spotlight was on mavacamten and its ... read more
Data from VALOR-HCM LTE suggest use of the cardiac myosin inhibitor mavacamten (Camzyos) could reduce the ... read more
For frail elderly patients with atrial fibrillation, switching from a vitamin K antagonist (VKA) treatment to ... read more